AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations
ByAinvest
Monday, Jul 21, 2025 8:03 pm ET1min read
Rowley Law PLLC is investigating iTeos Therapeutics' proposed acquisition by Concentra Biosciences for potential securities law violations. Stockholders will receive $10.047 and one contingent value right per share. The transaction is expected to close in Q3 2025. Shareholders interested in additional information can visit rowleylawpllc.com/investigation/itos.
Rowley Law PLLC has launched an investigation into potential securities law violations by iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors in relation to the proposed acquisition by Concentra Biosciences, LLC. The investigation centers on whether the acquisition process has complied with relevant securities laws.According to the latest press release [1], the acquisition deal, expected to close in the third quarter of 2025, offers stockholders of iTeos Therapeutics $10.047 and one contingent value right per share. The contingent value right entitles shareholders to additional shares or cash in the future, depending on the performance of Concentra Biosciences.
Shareholders interested in obtaining more information about the investigation can visit Rowley Law PLLC's website at [http://www.rowleylawpllc.com/investigation/itos/](http://www.rowleylawpllc.com/investigation/itos/) or contact Shane Rowley, Esq., at 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC specializes in representing shareholders in class actions and derivative lawsuits in complex corporate litigation. The firm has been involved in numerous high-profile cases and has a strong track record of advocating for shareholder rights.
The investigation by Rowley Law PLLC underscores the importance of thorough due diligence and transparency in corporate acquisitions. It serves as a reminder to investors to stay vigilant and seek legal advice if they suspect any irregularities in corporate transactions.
References:
[1] https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-iteos-therapeutics-inc-302509917.html
[2] https://www.marketscreener.com/news/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-iteos-therapeutics-inc-ce7c5cdcda8ef722
[3] https://www.morningstar.com/news/pr-newswire/20250721ny34377/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-iteos-therapeutics-inc
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet